









Markets
/
Stocks
/
nasdaq-elan
/

Elanco Animal Health Inc

ELAN

22.500USD

-0.350-1.53%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

11.17BMarket Cap

25.75P/E TTM



Elanco Animal Health Inc

22.500

-0.350-1.53%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Elanco Animal Health Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Elanco Animal Health Inc's Score

Industry at a Glance

Industry Ranking

11 / 159

Overall Ranking

29 / 4617

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

21.909

Target Price

-1.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Elanco Animal Health Inc Highlights

StrengthsRisks

Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 26.03, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 545.76M shares, decreasing 2.99% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 8.10M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.06.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 8.76, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.24B, representing a year-over-year increase of 4.81%, while its net profit experienced a year-over-year increase of 122.00%.

Score

Industry at a Glance

Previous score

8.76

Change



Financials

6.33

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.80

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.66

Key Metrics

Free cash flow

No Data

Elanco Animal Health Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.41, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 26.03, which is 35.99% below the recent high of 35.39 and 923.74% above the recent low of -214.39.

Score

Industry at a Glance

Previous score

7.41

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.13, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Elanco Animal Health Inc is 23.00, with a high of 25.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.00

Change

0.13

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Buy

Current Rating

21.909

Target Price

-4.12%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Elanco Animal Health Inc

ELAN

Apple Inc

AAPL

GE Vernova Inc

GEV

Tapestry Inc

TPR

FMC Corp

FMC

Avantor Inc

AVTR

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 9.57, which is higher than the Pharmaceuticals industry's average of 7.00. Sideways: Currently, the stock price is trading between the resistance level at 24.05 and the support level at 20.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.15

Change

0.42

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.039

Buy

RSI(14)

66.756

Neutral

STOCH(KDJ)(9,3,3)

78.507

Neutral

ATR(14)

0.627

High Vlolatility

CCI(14)

77.573

Neutral

Williams %R

16.576

Overbought

TRIX(12,20)

0.588

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

22.532

Sell

MA10

22.251

Buy

MA20

21.436

Buy

MA50

19.962

Buy

MA100

17.556

Buy

MA200

14.387

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 109.85%, representing a quarter-over-quarter increase of 5.85%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 82.90M shares, representing 16.69% of shares outstanding, with 0.84% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

82.90M

-0.03%

PRIMECAP Management Company

Star Investors

51.77M

+3.07%

Fidelity Management & Research Company LLC

48.24M

+25.93%

The Vanguard Group, Inc.

Star Investors

47.65M

-1.03%

Dimensional Fund Advisors, L.P.

22.75M

+11.15%

BlackRock Institutional Trust Company, N.A.

19.58M

-2.42%

T. Rowe Price Investment Management, Inc.

19.55M

+22.35%

Black Creek Investment Management, Inc.

19.25M

-12.67%

Fidelity Institutional Asset Management

16.64M

+7.01%

Citadel Advisors LLC

13.70M

+99.53%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 6.80, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.71. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.